CLINICAL IMPORTANCE OF ANTIPHOSPHOLIPID ANTIBODIES IN HEMODIALYSIS PATIENTS WITH VASCULAR ACCESS THROMBOSIS

Antiphospholipid antibodies can cause recurrent thrombotic attacks in some patients. Antiphospholipid antibodies are detected in patients with autoimmune disease especially systemic lupus erythematosus, infectious, malignant and drug-induced disorders. Vascular access-related complications are an important cause of morbidity. Antiphospholipid antibodies have been involved in thrombosis, and have been reported to be present in a high proportion of patients with chronic renal failure

We studied the prevalence of anticardiolipin antibodies and vasculer access thrombosis among patients undergoing haemodialysis. ACA were measured in 18 patients (10 man, 8 women) have no Vascular access thrombosis and 17 patients (10 women, 7 man) have recurrent Vascular access thrombosis . ACA was measured by a ELİ S A method. ACL Ig G was found as positive in 2 patients (%11.1) with have no vascular access thrombosis and was detected in one patient (%5.8) with vascular access thrombosis. ACL Ig M were found to be negative in all patients. Consequently, we concluded that no increase was detected in ACA existence in hemodialysis patients who developed thrombosis.